FDA Approves First Generic Single-Dose Influenza Treatment

The FDA's approval of a generic version of Xofluza marks a significant advancement in the treatment of influenza, particularly as it provides a single-dose option for patients. This development is expected to enhance treatment accessibility and potentially improve patient compliance during flu season. It reflects ongoing efforts to expand treatment options for common viral infections.